Efifcacy of Geiftinib for Young Patients with Unknown EGFR Gene Mutation in Advanced Lung Adenocarcinoma
10.3779/j.issn.1009-3419.2014.05.06
- VernacularTitle:吉非替尼治疗EGFR基因突变状态不明的青年晚期肺腺癌疗效分析
- Author:
LIU YUTAO
1
;
SHI YUANKAI
;
HU XINGSHENG
;
HAO XUEZHI
;
LI JUNLING
;
WANG ZIPING
;
WANG YAN
;
WANG HONGYU
;
ZHANG XIANGRU
;
SUN YAN
Author Information
1. 100021北京，中国医学科学院北京协和医学院肿瘤医院内科，抗肿瘤分子靶向药物临床研究北京市重点实验室
- Keywords:
Lung neoplasms;
Adenocarcinoma;
Geiftinib;
Young patient
- From:
Chinese Journal of Lung Cancer
2014;(5):401-405
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Lung cancer in young patients (less or equal to 45 years) is relatively rare. We explored the effcacy and survival of Geiftinib for young patients with unknown epidermal growth factor receptor (EGFR) gene mutation of advanced lung adenocarcinoma. Methods hTe clinical data of 55 young patients with unknown EGFR gene mutation in advanced lung adenocarcinoma referred to the Cancer Hospital&Institute, Chinese Academy of Medical Sciences from Jan 2006 through Dec 2010 were analyzed retrospectively. Results Of 55 young patients enrolled, the me-dian age was 41 years. hTe objective response rate and disease control rate were 43.6%and 90.9%, respectively. hTe median progression-free survival (PFS) was 9.0 months. Among the factors analyzed, brain metastasis had signiifcant effect on PFS (P=0.017). hTe median overall survival (OS) was 24.0 months. hTe independent prognostic factors to signiifcantly improve OS included non-smoking history (P=0.028) and receiving other anti-cancer treatment atfer Geiftinib therapy (P<0.001). Conclusion hTe median PFS and OS of the young patients with Unknown EGFR gene mutation in advanced lung adeno-carcinoma were similar with general population.
